| Azacitidine and venetoclax in previously untreated acute myeloid leukemia CD DiNardo, BA Jonas, V Pullarkat, MJ Thirman, JS Garcia, AH Wei, ... New England Journal of Medicine 383 (7), 617-629, 2020 | 2047 | 2020 |
| Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma MV Mateos, MA Dimopoulos, M Cavo, K Suzuki, A Jakubowiak, S Knop, ... New England Journal of Medicine 378 (6), 518-528, 2018 | 1016 | 2018 |
| Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma JM Connors, W Jurczak, DJ Straus, SM Ansell, WS Kim, A Gallamini, ... New England Journal of Medicine 378 (4), 331-344, 2018 | 777 | 2018 |
| Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non–germinal center B-cell diffuse large B-cell lymphoma A Younes, LH Sehn, P Johnson, PL Zinzani, X Hong, J Zhu, C Patti, ... Journal of Clinical Oncology 37 (15), 1285-1295, 2019 | 561 | 2019 |
| Daratumumab-based treatment for immunoglobulin light-chain amyloidosis E Kastritis, G Palladini, MC Minnema, AD Wechalekar, A Jaccard, HC Lee, ... New England Journal of Medicine 385 (1), 46-58, 2021 | 437 | 2021 |
| Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission AH Wei, H Döhner, C Pocock, P Montesinos, B Afanasyev, H Dombret, ... New England Journal of Medicine 383 (26), 2526-2537, 2020 | 369 | 2020 |
| Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial P Moreau, MA Dimopoulos, J Mikhael, K Yong, M Capra, T Facon, ... The Lancet 397 (10292), 2361-2371, 2021 | 306 | 2021 |
| Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy Z Acar, A Kale, M Turgut, S Demircan, K Durna, S Demir, M Meriç, ... Journal of the American College of Cardiology 58 (9), 988-989, 2011 | 287 | 2011 |
| Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study R Diz-Kucukkaya, A Hacıhanefioglu, M Yenerel, M Turgut, H Keskin, ... Blood, The Journal of the American Society of Hematology 98 (6), 1760-1764, 2001 | 264 | 2001 |
| Randomized phase III study of alisertib or investigator’s choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma OA O’Connor, M Özcan, ED Jacobsen, JM Roncero, J Trotman, J Demeter, ... Journal of Clinical Oncology 37 (8), 613-623, 2019 | 127 | 2019 |
| Hemostatic efficacy of Ankaferd Blood Stopper® in a swine bleeding model H Bilgili, A Kosar, M Kurt, IK Onal, H Goker, O Captug, A Shorbagi, ... Medical Principles and Practice 18 (3), 165-169, 2009 | 127 | 2009 |
| The QUAZAR AML-001 maintenance trial: results of a phase III international, randomized, double-blind, placebo-controlled study of CC-486 (oral formulation of azacitidine) in … AH Wei, H Döhner, C Pocock, P Montesinos, B Afanasyev, H Dombret, ... Blood 134, LBA-3, 2019 | 118 | 2019 |
| In vitro anti-bacterial activities of Ankaferd medicinal plant extract N Akkoc, M Akcelik, IC Haznedaroglu, H Goker, M Turgut, S Aksu, ... Turkiye Klinikleri Tip Bilimleri Dergisi 29 (2), 410-415, 2009 | 83 | 2009 |
| Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience H Bekoz, M Ozbalak, N Karadurmus, S Paydas, A Turker, T Toptas, ... Annals of Hematology 99, 2565-2576, 2020 | 82 | 2020 |
| Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study M Mohty, E Terpos, MV Mateos, M Cavo, S Lejniece, M Beksac, ... Clinical Lymphoma Myeloma and Leukemia 18 (10), e401-e419, 2018 | 79 | 2018 |
| Predicting survival for multiple myeloma patients using baseline neutrophil/lymphocyte ratio E Kelkitli, H Atay, F Çilingir, N Güler, Y Terzi, D Özatlı, M Turgut Annals of hematology 93, 841-846, 2014 | 76 | 2014 |
| Relation between hemostatic parameters and prognostic/predictive factors in breast cancer E Yigit, G Gönüllü, İ Yücel, M Turgut, D Erdem, B Çakar European journal of internal medicine 19 (8), 602-607, 2008 | 73 | 2008 |
| Isatuximab plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (IKEMA): interim analysis of a phase 3, randomized, open … P Moreau, MA Dimopoulos, J Mikhael, K Yong, M Capra, T Facon, ... European Hematology Association, 11-21, 2020 | 70 | 2020 |
| Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the … P Lugtenburg, I Avivi, H Berenschot, O Ilhan, JP Marolleau, A Nagler, ... Haematologica 102 (11), 1913, 2017 | 68 | 2017 |
| Preoperative localization of parathyroid carcinoma using Tc-99m MIBI MT Kitapci, G Tastekin, M Turgut, B Caner, A Kars, I Barista, C Bekdik Clinical nuclear medicine 18 (3), 217-219, 1993 | 68 | 1993 |
